clinical trial · NCT06549790
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences·phase1·recruiting·n = 124
Relapsed/Refractory Acute Myeloid LeukemiaNMS-03597812
brief summary
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.
started
Oct 16, 2024
primary completion
Sep 15, 2029
completion
May 15, 2030
last updated
Oct 31, 2025
official title
A Phase Ia/Ib Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Including Patients With TP53 Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol